Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

26.73 +0.30 (+1.15%)

Delayed Quote Updated: 9:53 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Maze Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

November 06, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

November 06, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

November 04, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

October 06, 2025

Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech

From Maze Therapeutics, Inc.

Via GlobeNewswire

Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗

September 17, 2025

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

Via MarketBeat

What's going on in today's session ↗

September 11, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗

September 11, 2025

Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 11, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

September 11, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗

September 11, 2025

Via Benzinga

Thursday's session: gap up and gap down stocks ↗

September 11, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗

September 11, 2025

Shares catapulted Thursday after its experimental treatment for a rare, genetic disease blew past expectations.

Via Investor's Business Daily

Discover the top movers in Thursday's pre-market session. ↗

September 11, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 11, 2025

Via Benzinga

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

September 11, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

September 11, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

September 02, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Inc (NASDAQ:MAZE) Reports Narrower Q2 2025 Loss, Extends Cash Runway to 2027 ↗

August 12, 2025

Maze Therapeutics reports Q2 2025 earnings with a narrower loss than expected, extends cash runway to 2027, and advances kidney disease clinical trials.

Via Chartmill

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 12, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 28, 2025

Via Benzinga

This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

July 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 16, 2025

Via Benzinga

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

July 10, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

May 29, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 28, 2025

Via Benzinga

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

May 14, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 13, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 25, 2025

Via Benzinga

Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

April 11, 2025

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.